Why Arena Pharmaceuticals Will Underperform In 2013 [View article]
Only specialists will be prescribing at launch can't be right. There is no requirement for reps to pass by more than half their potential sales due to what? Your opinion that they should conduct some specialist only trial? Ridiculous. Even if this were true it would not matter, there are no general practitioners anymore, other than the ones who always do the same thing, refer you to a specialist.
Why Arena Pharmaceuticals Will Underperform In 2013 [View article]
You have the right idea. But not too sure about the short squeeze. We've been expecting that one since approval and it never came close to materializing, the short interest only got larger. From about 30M up to 60M. Kinda weird if you ask me, or fishy. I wouldn't worry about this one going under $7 again though.Or not much anyway. And the fluctuations it has going fast between $8 and $9.50 are great for selling calls and I guess for selling puts when overbought. I been mainly selling calls for weekly income. Easy money.
Arena Gets Highly Anticipated DEA Scheduling Decision [View article]
I think what he was referring to is the fact that scheduling this drug was a waste of time and an abuse of gov't power. There was no reason to even consider this drug for a scheduling number. The tests it underwent showed clearly there is no chance anyone would ever want to abuse it. Out of all participants or test subjects in the DEA testing for abuse potential there were zero who answered they would want to abuse it among other methods of trying to see if there was the potential for abuse. That is my opinion of it too. It was a waste of time and taxpayer dollars and never should have been done. Typical abuse and waste of taxpayer money.
Today's Market News To Trade On: 5 Stocks Moving On News [View article]
On ARNA you are quite fair and very "safe" with your assessment. A little more research by you would reveal your hesitancy is based upon unfounded scare tactics thrown to and fro by the vast number of short sellers in it. These shorts are nothing less than bag holders to a huge magnitude. They were dancing around the fire and tossing vindictives toward all longs for so long they forgot to close their short positions when the timing was right, letting their greed control their actions. Now they are writhing in pain and total complete fear and frustration that their entire portfolio is about to crash around them very very soon now. As soon as the DEA releases its scheduling for Belviq, which those who are thinking clearly and have done the research on this company can honestly tell you, Belviq is very likely to receive schedule IV and possibly even a V. Making it easily prescribed and further able to expand its market in this exclusive area of health. Their profit potential is very high with royalties coming off the net income not the gross after taxes and others are paid. ARNA is about to make a lot of short sellers very poor, very destitute and in a position they have feared now since receiving FDA approval. Their slur campaign has been thrown on its face and its leader is The Street.com. Just wait and see how fast they declare bankruptcy or at the very least a massive loss due to their barrage of lies trying to drive the price down in ARNA. I can't imagine who owns the majority of those 50M short shares out there. Whoever they are, they are about to be broker than they never thought they would be. With the number of shares short, they have recently made the naked short list. So now the dealers and brokers are scrambling too. Your assessment and others is dead on right though, ARNA is a great trading play and a great position to hold long term as a core holding. It has done nothing but generate returns for anyone long or selling calls.
Picking The Weight Loss Winner In The Arena Vs. Vivus War [View article]
Pretty poorly written article. Numbers on Arena's efficacy are wrong by a huge amount. Try 11% for those who completed the study and even higher when you narrow the field to just diabetics. Safety for Arena's is a non factor and always was. The prior scare was cooked up by those huge numbers of short sellers at the time of the first FDA NDA meeting gathering opinion and used to smear Arena by biased FDA officials. FDA was and is tainted in their position due to Cabinet Secretary of FDA's husband runs a hedge fund shorting ARNA at the time, the former head of the weight loss dept. at FDA had left and was the new CEO of one of Arena's competitors when the first panel meeting took place also. The big scare of tumor possibilities was totally fabricated using an incorrect method to arrive at those conclusions about tumors. This article is another example of poor DD by an anal ist.
Arena Pharmaceuticals Outlines Its Path To Profitability [View article]
You wrote- "Interesting points, but ARNA is still clearly in the bottom 20% of biotech stocks for institutional ownership." What you're forgetting is ARNA has just defeated and I mean just now defeating the institutional industry wide short story against it. Now that that story has been shown to be false, they are covering and buying long. Next filing period will show huge increase I bet. It takes time to get those numbers.
Arena Pharmaceuticals Outlines Its Path To Profitability [View article]
Yeah, deciphering any company's reports is difficult but a biotech's are extra confusing it seems. You're right about them shooting from the hip, they also all copy the big boy and do not deviate, even when their shown to be completely wrong, their pride is hurt and they cling desperately to their made up story to save face. But in the end the egg on that face is thick as mud.
Arena Pharmaceuticals Outlines Its Path To Profitability [View article]
Ha ha ha. Another fool in the rain who has done nothing but read Adam Fowerstine articles on the Street dot com. Or possibly have done no research into why those ridiculous lies told to crash the stock once have been found to be completely fabricated lies as part of a campaign to short this stock. Too bad most of them held those shorts like you did from the low $2 per share. Man I bet that hurts, sure am glad I did my own research on this company and decided AF was either an idiot or a liar. I decided he is a liar in it for the pump and dump short sell. You shouldn't put any stock into what Adam writes, he does nothing but twitch when his puppet masters pull his strings. He has gotten so terrible the Street has hired a new Arena hit man to take his place. The Street must hold several million shares short because they more than any other outlet, if there are any others still, is still recommending to short Arena. Even now with FDA approval and DEA scheduling due any day and expected to be so soft it will be a non factor other than to allow the stock to rise even higher in price. I recommend covering those short shares ASAP, as soon as DEA publishes the scheduling, the share price is up another $5 minimum.
I would put absolutely zero weight to anything AF says or writes. He is an untrustworthy source of any info. Just pass whatever he says by and continue onto a reliable source, which is any source other than AF.
Arena: DEA Schedule IV Will Make Belviq The Obesity Blockbuster Drug [View article]
To reality trader: Hahahahahahahahaahahah... you're still short and feeling the death grip of your increased short position when mistaking again the classification from the DEA. FYI, Belviq is NOT a hallucinogen, it causes absolutely no hallucinations. The only hallucinations here are yours. Cover now before you get completely crushed by your bad calls.
Buy Arena, Sell Vivus As Qsymia's European Approval In Doubt [View article]
Your price target on Arena should be much higher. No competition alone warrants a share price over $20 easily. Now with EU most likely to not approve Vivus for sale there, and Orex nowhere to be seen anytime soon leaves the one true safe drug for EU and decreased confidence in US over Vivus means increased confidence for Arena's Belviq. Translated as more sales for Arena. A lot more. Shorts are advised to cover now before the rejection is official. Hedge funds and other shorts will no doubt continue their lie campaign with the used once already and failed method of trying to group Arena with the losers in the obesity drug field citing useless data to scare the uninformed and in turn lowering Arena's share price. What is funny is how they for the most part now all say that Arena has a better safety profile but then try to compare it to an unsafe drug with a profile known to cause harmful side effects. BOOO
Augusta Resource Corp. Fights The Red Tape [View article]
Good luck trying to get screwballs to stop being idiots. Those total extreme dingbats live to create hardships for anyone not themselves. It is what gives them a sense of worth and pleasure at the same time. I can see them in my minds eye, congratulating each other at each new impasse they put forth. A continual broadfront of challenges to a single company just trying to create some jobs and income for people who after the mine does finally get permitted, will work there or at the least earn their living due to the offshoot economy the mine will create in the area. To invest in this now would be a bad idea. Until the jaguar preserve thing gets put out to pasture due to the realization that there are no jaguars anywhere in the area, it will be used as a valid argument by the wackos.
Merck Gives InSite A Gift; What Does It Mean? [View article]
Maybe Merck should just buy Insite and do it that way. Keep it all for themselves and out of the competitions hands. Or Pfizer or Allergan can always do the buying, doesn't matter to me. Meanwhile Insite can get its new drug approved and create interest in the company to grow.
Why Arena Pharmaceuticals Will Underperform In 2013 [View article]
Why Arena Pharmaceuticals Will Underperform In 2013 [View article]
Arena Gets Highly Anticipated DEA Scheduling Decision [View article]
That is my opinion of it too. It was a waste of time and taxpayer dollars and never should have been done. Typical abuse and waste of taxpayer money.
Today's Market News To Trade On: 5 Stocks Moving On News [View article]
Picking The Weight Loss Winner In The Arena Vs. Vivus War [View article]
Arena Pharmaceuticals Outlines Its Path To Profitability [View article]
"Interesting points, but ARNA is still clearly in the bottom 20% of biotech stocks for institutional ownership."
What you're forgetting is ARNA has just defeated and I mean just now defeating the institutional industry wide short story against it. Now that that story has been shown to be false, they are covering and buying long. Next filing period will show huge increase I bet. It takes time to get those numbers.
Arena Pharmaceuticals Outlines Its Path To Profitability [View article]
Arena Pharmaceuticals Outlines Its Path To Profitability [View article]
Arena Pharmaceuticals Outlines Its Path To Profitability [View article]
Arena Pharmaceuticals Outlines Its Path To Profitability [View article]
Biotech Weekend Recap: Tug Of War [View article]
Arena: DEA Schedule IV Will Make Belviq The Obesity Blockbuster Drug [View article]
Hahahahahahahahaahahah... you're still short and feeling the death grip of your increased short position when mistaking again the classification from the DEA. FYI, Belviq is NOT a hallucinogen, it causes absolutely no hallucinations. The only hallucinations here are yours. Cover now before you get completely crushed by your bad calls.
Buy Arena, Sell Vivus As Qsymia's European Approval In Doubt [View article]
Augusta Resource Corp. Fights The Red Tape [View article]
Merck Gives InSite A Gift; What Does It Mean? [View article]